Video: Understanding Pharmacogenomics (Stanford course BIOMEDIN 204)

What is it?

This videorecorded course is an in-depth view of the genetic factors that affect human responses to therapeutic drugs. It was presented as Stanford University's "BIOMED 204: Pharmacogenomics" by Profs. Russ Altman and Caroline Thorn in 2006.

The course features applications of PharmGKB. This Web-accessible database aids researchers understand how genetic variation among individuals contributes to differences in reactions to drugs.

Who is it for?

The course is given from a medical perspective and is especially well-suited to clinicians who wish to understand why patients can react so differently to a standard dosage of an FDA-approved drug.

What's in it?

These videorecordings total 9 hours and address the following topics:

introduction to pharmacogenomics and pharmacology
human polymorphisms, frequencies, significance, and populations
informatics in pharmacogenomics
genotype-to-phenotype, and phenotype-to-genotype approaches
drug discovery and validation; genomic variation discovery and genotyping; adverse drug reactions and interactions
pathways of drug metabolism
cancer pharmacogenomics

Lectures topics:

Lecture 1: Introduction; roots of pharmacogenomics; understanding the genome and genetics; genotyping; classic examples of genetic determinants of drug response.
Lecture 2: Classical pharmacogenetics examples and their effects on drug pharmacokinetics: TPMT and 6-mercaptourine; CYP2D6 and codeine; CYP2C9 and warfarin
Lecture 3: How genotype influences phenotype; selection of polymorphisms; linkage disequilibrium.
Lecture 4: Drug discovery and validation
Lecture 5: Terminologies for describing pharmacogenomic concepts, including ontologies; adverse drug reactions; drug interactions.
Lecture 6: Cancer pharmacogenomics

Note: Access is restricted to the Stanford community and requires a SUNetID.

What is it for?

Understanding the essentials of why and how the effects of common drugs are influenced by a patient's genetic determinants.

These determinants and their pharmacological effects are often known or knowable. Understanding pharmacogenomics can prevent serious negative outcomes and side effects (including death), as well as increase the likelihood of beneficial effects from drug therapy.

Other resources

All Lane resources involving pharmacogenomics.
All PubMed references pertaining to pharmacogenomics and published by the Altman group ("Helix Group").
All PubMed references pertaining to pharmacogenomics.

Lane Medical Library powered by LaneConnex Technology